Glioblastoma multiforme (GBM) corresponding to World Health Organization (WHO) grade IV glioma is the most deadly brain tumor in adults with a median overall survival of approximately 15 months from diagnosis \[[@B1]\]. Despite intensive treatment including surgical resection, radiotherapy, and chemotherapy the average 5-year survival rate is less than 10% \[[@B1],[@B2]\]. Introduction of temozolomide in 2005 resulted in a modest increase in survival, mostly restricted to younger patients \[[@B3]\]. One of the many challenges with glioblastomas is the infiltrative and migrating nature of the cancer cells that spread and hide in normal brain regions, a mimic of embryonic glial propagation. Another challenge is the notorious resistance to chemo- and radiotherapy, in part related to the cellular heterogeneity often seen in glioblastoma. Over the past decade, omics-technologies have resulted in a tremendous increase in knowledge of the epigenetic, genetic, and transcriptome alterations found in glioblastomas \[[@B4]\]. This has led to definitions of molecularly distinct subtypes, including the gene expression-based subtypes known as proneural, neural, classical, and mesenchymal types. In a rapidly developing field, there are now additional molecular markers and classifications of brain tumors as reflected in the 2016 update of the WHO Classification of Tumors of the Central Nervous System \[[@B1]\]. For example, point mutations in the isocitrate dehydrogenase-1 (*IDH-1*) and *IDH-2* genes classify glioblastoma into IDH-mutant glioblastomas, characterized by epigenetic hypermethylation and proneural gene expression, and IDH-wildtype glioblastomas (neural, proneural, mesenchymal, or classical gene expression patterns) \[[@B1],[@B7]\]. If no mutations are present in *IDH*, the glioblastomas are known as IDH-wildtype (these often correspond to the so-called primary glioblastomas that develop *de novo*). Mutations in the *IDH1* and 2 genes initially occur in WHO grade II and grade III gliomas and are associated with improved survival \[[@B1],[@B7]\]. The majority of glioblastomas can also be divided into molecular subgroups based on mutations in the telomerase reverse transcriptase (*TERT*) promoter \[[@B8],[@B9]\]. These molecular subgroups use different mechanisms to maintain the telomeres, either *TERT* promoter mutation causing telomerase activation or mutations in *ATRX* leading to an alternative lengthening of telomeres \[[@B10]\]. The molecular understanding of gliomas including the glioblastomas is rapidly evolving, and a complete discussion on this topic is outside the scope of this commentary. Regarding the glioblastomas, presence or absence of *IDH* mutation, *MGMT* (O(6)-methyl guanidine-DNA-methyltransferase) promoter methylation, and *TERT* promoter mutations are of particular interest to analyze \[[@B9]\].

Despite intense research and many great discoveries over the past decade, there is still a need to find additional sharp and reliable, easy to analyze biomarkers that can further improve the classification and treatment of brain tumors. Such markers could include diagnostic biomarkers to enable more accurate classification, prognostic biomarkers that inform about a likely cancer outcome and predictive biomarkers to give hints about the best treatment strategy. Today, some glioma-specific molecular biomarkers include *IDH* mutations (grades II, III gliomas), chromosomal region 1p19q deletion, and *MGMT* promoter methylation \[[@B9]\].

Following a previous comparison of gene expression profiles between gliomas with different grades that revealed frequent overexpression of insulin-like growth factor binding protein 2 (*IGFBP2*) in glioblastomas \[[@B12]\], Yuan et al. \[[@B11]\] set out to investigate *IGFPB2* mRNA levels in a larger cohort of glioblastomas. What is known about IGFBP2 in brain tumors? IGFBPs bind and regulate the bioavailability and signaling activity of circulating IGF-I and IGF-II \[[@B13]\]. Often, IGFBP2 expression positively correlates with tumor aggressiveness and other known cancer markers \[[@B13]\]. Functionally, IGFBP2 has been established as a driver of glioma progression to a higher grade \[[@B14],[@B15]\]. IGFBP2-driven tumors are dependent on the continued expression of IGFBP2, as knockdown led to a significant decrease in tumor progression and prolonged survival. Exogenous IGFBP2 increases the proliferation and invasive capacity of the glioma cells, and induces chemoresistance, while knockdown of IGFBP2 resulted in both decreased invasiveness and tumorigenicity in nude mice \[[@B14],[@B15]\]. Evidence suggests that IGFBP2 engages the Akt signaling pathway and at least in some settings collaborates with platelet-derived growth factor β (PDGFB) in the development of glioma \[[@B14]\]. Furthermore, IGFBP2 is overexpressed within the stem cell compartment of glioblastomas and is needed for clonal expansion and proliferation of glioma stem cells, and IGFBP2 may also contribute to tumor progression by enriching for glioma stem cells and boosting their survival \[[@B16]\].

*In situ* analysis of biomarkers is of interest because it allows visualization of the expression pattern within the tumor in relation to other parameters of interest. RNAscope is a novel RNA *in situ* hybridization technology with a unique probe design. This innovative technique may achieve detection of single molecules in individual cells and the assay can be multiplexed if needed. As mentioned, *IGFBP2* overexpression is common in high-grade glioma and *IGFBP2* is a prognostic factor for poor survival \[[@B17]\]. One may wonder why Yuan et al. \[[@B11]\] set out to re-investigate something already known nearly two decades ago \[[@B12]\]. Well, the answer is that studies of *IGFBP2* transcript expression in glioblastoma biopsies detected by an *in situ* method were very few, but as of today, the techniques have been improved and could either confirm or challenge previous results. Innovative technologies could present more robust and reliable data leading to, for example revival and repurposing of 'forgotten' biomarkers. In the present study, RNAscope probe was used to detect the expression of *IGFBP2* mRNA in 180 glioblastomas \[[@B11]\]. The analysis revealed 16.9 months median overall survival for the patients with low *IGFBP2* mRNA levels, but only 11.6 months for patients with high *IGFBP2*, which is a striking difference. In other datasets this difference appears less pronounced, but remains significant \[[@B17]\]. Presumably, the resolution of RNAscope allows for a sharper distinction of the expression patterns than immunohistochemistry. It is of further interest to test *IGFBP2* levels and its prognostic value on to already established biomarkers since it may, for example, help to select patients with poor prognosis and who may benefit from more rapid or aggressive therapy. Yuan et al. \[[@B11]\] therefore divided the glioblastoma patients into subgroups. Combining *IGFBP2* mRNA expression and *TERT* promoter status, the survival analysis showed that GBM patients harboring wild-type *TERT* promoter had the longest median overall survival time of 19.6 months. In patients with mutation in the *TERT* promoter, those that had low *IGFBP2* mRNA presented with a median overall survival of 14.8 months, and patients with both mutation in the *TERT* promoter and high levels of *IGFBP2* mRNA had the shortest overall survival of 9.8 months. These are highly distinct differences in survival between the groups.

Recently, IGFBP2 has been put forward as a specific prognostic marker in IDH-mutant low-grade glioma patients \[[@B18]\]. It turns out that IDH-mutant glioma patients generally manifest low *IGFBP2* expression, which is associated with improved survival independent of *IDH* mutational status, whereas high *IGFBP2* expression results in worse survival than in the IDH-wildtype group. Thus for the IDH-mutant group *IGFBP2* is prognostic \[[@B18]\]. In the present study focusing on glioblastomas, Yuan et al. \[[@B11]\] found in agreement a negative correlation between the presence of *IDH* mutation and high level of *IGFPBP2* mRNA. Additional analysis of the data accumulated in relation to *IDH* are certainly of interest.

In summary, *IGFBP2* mRNA served as an independent prognostic biomarker in glioblastomas. It was also revealed that *IGFBP2* mRNA might serve as a potential prognostic indicator together with *TERT* promoter status \[[@B11]\]. The data shown in the present study \[[@B11]\] and in other recent ones \[[@B17],[@B18]\], reveal that IGFBP2 stands out among many other candidate molecular biomarkers. However, biomarkers need to be easy to analyze and provide clear answers in order to improve classification or treatment. With this perspective RNAscope analysis of *IGFBP2* appears demanding, but one may consider it in some settings. Could there be other proxies for *IGFBP2* that are easier to analyze? Of particular interest would be minimally invasive biomarkers for diagnosis and as measures of response to therapeutic interventions, for example those found in serum or that can be detected by imaging. Additional studies are warranted on this topic. Finally, it should be mentioned that IGFBP2 most likely plays an important role in the immunologic processes of glioblastomas including immunosuppressive checkpoints and various signaling pathways \[[@B17],[@B19]\]. Moreover, neutralizing antibodies against IGFBP2 impaired IGFBP2-mediated oncogenic signaling pathways and inhibited the spread of tumor cells \[[@B20]\]. IGFBP2 therefore remains as a candidate biomarker and potential therapeutic target in glioma therapy, perhaps immunotherapy in particular. Further research into its functional roles and regulatory mechanisms during glioma progression may provide additional insights into therapeutic approaches in the management of this deadly disease.
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